Alzheimer's
disease (AD) is a progressive, neuro-degenerative
disease characterized by memory loss, language deterioration, impaired
visuospatial skills, poor judgment, indifferent attitude, but preserved
motor function. AD usually begins after age 65, however, its onset may
occur as early as age 40, appearing first as memory decline and, over
several years, destroying cognition, personality, and ability to function.
Confusion and restlessness may also occur. The type, severity, sequence,
and progression of mental changes vary widely. The
early symptoms of AD, which include
forgetfulness and loss of concentration, can be missed easily because
they resemble natural signs of aging. Similar symptoms can also result
from fatigue, grief, depression, illness, vision or hearing loss, the
use of alcohol or certain medications, or simply the burden of too many
details to remember at once.
Is there
any treatment? There is no cure for AD
and no way to slow the progression of the disease. For some people in
the early or middle stages of the disease, medication such as tacrine
may alleviate some cognitive symptoms. Aricept (donepezil) and Exelon
(rivastigmine) are reversible acetylcholinesterase inhibitors that are
indicated for the treatment of mild to moderate dementia of the Alzheimer's
type. Also, some medications may help control behavioral symptoms such
as sleeplessness, agitation, wandering, anxiety, and depression. These
treatments are aimed at making the patient more comfortable.
What research is being
done? The
NINDS conducts and supports research on neuro-degenerative and dementing
disorders, including AD. For example, although the cause of AD is still
unknown, new research has shown that a vaccine, aimed at preventing
or reversing the formation of AD-associated pathologic lesions, might
be a useful therapy. Recent results using a transgenic mouse model suggest
that immunological interventions may retard and even reverse the development
of some of the pathologic changes associated with AD. Early clinical
trials to test the vaccine are still in progress but offer hope for
a future therapy.
The National Institute on Aging and
the
National Institute of Mental Health support research related
to AD.